** Shares of drugmaker Perrigo PRGO.N rise 20% to $28.98, highest in about three months
** Co says on an investor call that it will lay out plans to "consumerize, simplify and scale its global self-care platform"
** Expects 2025 adj profit of $2.90 to $3.10 per share, compared to analysts' estimate of $3.04 per share
** Sees 2025 net sales growth of 1% to 3%; organic compound annual sales growth of 2.5% to 4.5% for 2025 to 2027
** Co posted late on Thursday Q4 sales of $1.14 bln compared to analysts' estimate of $1.2 bln, according to data compiled by LSEG
** Co reported Q4 adj profit of 93 cents per share in line with estimates
** PRGO has fallen 25% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。